ASYMMETRIC UREAS AND MEDICAL USES THEREOF

CROSS-REFERENCES TO RELATED APPLICATIONS

1. This application claims priority under 35 U.S.C. § 365(b) to PCT Application No. PCT/CN2011/000298, filed Febuary 25, 2011, and under 35 U.S.C. § 119(e) to Provisional U.S. Application No. 61/466,070, filed March 22, 2011. The disclosure of PCT Application No. PCT/CN2011/000298 and U.S. Application No. 61/466,070 ~~are hereby incorporated by reference in their entirety~~.

FIELD OF THE INVENTION

2. The present invention relates to novel compounds based on asymmetric ureas, and medical uses thereof, particularly in the treatment of medical conditions modulated by the ghrelin receptor.

BACKGROUND

3. The growth hormone secretagogue receptor (GHS-R) regulates a number of physiological processes, including growth hormone (GH) release, metabolism, and appetite. Ghrelin, a circulating hormone produced predominantly by endocrine cells in the stomach, is its endogenous ligand. Ghrelin is a 28 amino acid peptide with an acyl side chain required for biological activity (Kojima et al., Nature, 402, 656-660, 1999). Ghrelin has been shown to stimulate growth hormone (GH) release and to increase food intake when administered both centrally and peripherally (Wren et al., Endocrinology, 141, 4325-4328, 2000).

4. Endogenous levels of ghrelin rise on fasting and fall on re-feeding in humans (Cummings et al., Diabetes, 50, 1714-1719, 2001). Ghrelin also appears to play a role in maintaining long term energy balance and appetite regulation. Chronic administration of ghrelin in rodents leads to hyperphagia and weight gain that are independent of growth hormone secretion (Tschop et al., Nature, 407, 908-913, 2000). Circulating ghrelin levels decrease in response to chronic overfeeding and increase in response to chronic negative energy balance associated with anorexia or exercise. Obese people generally have low plasma ghrelin levels (Tschop et al., Diabetes, 50, 707-709, 2001) accordingly to the physiological response of the body in reducing calories intake. Intravenous ghrelin is effective in stimulating food intake in humans. A recent study showed a 28% food intake

desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, and P. G. M. Wuts and T.W.Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 2006~~; which are hereby incorporated by reference~~. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.

7. Definition of Terms

40. The term "alkyl" refers to a linear or branched-chain saturated hydrocarbyl substituent (i.e., a substituent obtained from a hydrocarbon by removal of a hydrogen) containing from one to twenty carbon atoms; in one embodiment from one to twelve carbon atoms; in another embodiment, from one to ten carbon atoms; in another embodiment, from one to six carbon atoms; and in another embodiment, from one to four carbon atoms. Examples of such substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and tert-butyl), pentyl, iso-amyl, hexyl and the like.

41. The term "alkenyl" refers to a linear or branched-chain hydrocarbyl substituent containing one or more double bonds and from two to twenty carbon atoms; in another embodiment, from two to twelve carbon atoms; in another embodiment, from two to six carbon atoms; and in another embodiment, from two to four carbon atoms. Examples of alkenyl include ethenyl (also known as vinyl), allyl, propenyl (including 1-propenyl and 2-propenyl) and butenyl (including 1-butenyl, 2-butenyl and 3-butenyl). The term "alkenyl" embraces substituents having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations.

42. The term "benzyl" refers to methyl radical substituted with phenyl, i.e., the following structure: .

43. The term "carbocyclic ring" refers to a saturated cyclic, partially saturated cyclic, or aromatic ring containing from 3 to 14 carbon ring atoms ("ring atoms" are the atoms

and other factors. Therapeutically effective amounts of compounds of Formula (I) may range from approximately 0.01 microgram per Kg (μg/Kg) body weight per day to about 100 mg/Kg body weight per day, or from about 0.1 μg /Kg/day to about 10 mg/Kg/day, or from about 1 μg /Kg /day to about 5 mg/ Kg /day, or from about 10 μg /Kg/day to about 5 mg/Kg/day, or from about 100 μg /Kg/day to about 5 mg/Kg/day, or from about 500 μg /Kg/day to about 5 mg/Kg/day.

110. One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of a compound of Formula I for a given disease. In some other forms, disclosed are methods of preventing and/or treating a subject, further comprising one or more therapeutic agents.

B. More Definitions of Terms

111. Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are ~~hereby incorporated by reference into this application~~ in order to more fully describe the state of the art to which this pertains. ~~The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.~~

1. A, an, the

112. As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.

2. Abbreviations

113. Abbreviations, which are well known to one of ordinary skill in the art, may be used (e.g., "h" or "hr" for hour or hours, "g" or "gm" for gram(s), "mL" for milliliters, and "rt" for room temperature, "nm" for nanometers, "M" for molar, and like abbreviations).

3. About

114. The term "about," when used to modify the quantity of an ingredient in a composition, concentrations, volumes, process temperature, process time, yields, flow rates, pressures, and like values, and ranges thereof, employed in describing the embodiments of the disclosure, refers to variation in the numerical quantity that can occur, for example,

14. Optional

124. "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

15. Or

125. The word "or" or like terms as used herein means any one member of a particular list and also includes any combination of members of that list.

16. Publications

126. Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are ~~hereby incorporated by reference into this application~~ in order to more fully describe the state of the art to which this pertains. ~~The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.~~

17. Subject

127. As used throughout, by a "subject" is meant an individual. Thus, the "subject" can include, for example, domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.) mammals, non-human mammals, primates, non-human primates, rodents, birds, reptiles, amphibians, fish, and any other animal. The subject can be a mammal such as a primate or a human. The subject can also be a non-human.

18. Treating

128. By "treating" or "treatment" is meant the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. These terms include active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. These terms can mean that the symptoms of the underlying disease are reduced, and/or that one or more of the underlying cellular, physiological, or biochemical causes or mechanisms causing the symptoms are reduced. It is understood that reduced, as used in this context, means relative to the state of the disease, including the molecular state of the disease, not just the physiological state of the disease. In

CLAIMS

What is claimed is:

1. A compound of formula (I), or a pharmaceutically acceptable salt or adduct thereof,



Formula (I)

wherein:

R is selected from the group consisting of aryl, arylalkyl, carbocyclic ring, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl, optionally substituted with one or more independent R^{103} substituents;

R_1 is selected from the group consisting of hydrogen, hydroxy, hydroxyalkyl, amino, alkyl, alkenyl, cycloalkyl, halogen, alkoxy, alkoxyalkyl, $-C(O)R^{101}$, $-C(O)OR^{101}$, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl, each optionally independently substituted with one or more independent R^{103} substituents;

R_2 is hydrogen or R_1 and R_2, together with the atoms connecting the same, form a fused or non-fused mono, bicyclic or tricyclic heterocyclic or carbocyclic ring which is optionally independently substituted with one or more R^{103} substituents;

R_3 is selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, $-C(O)R^{101}$, $-C(O)OR^{101}$, $-C(O)NR^{101}R^{102}$, $-S(O)_2R^{102}$, $-SR^{101}$ and $-S(O)_2NR^{101}R^{102}$, optionally substituted with one or more independent R^{103} substituents;

R_4 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, $-OR^{103}$, $NR^{101}R^{102}$, $-C(O)R^{101}$, $-C(O)OR^{101}$, $-C(O)NR^{101}R^{102}$, $-alkylNR^{101}R^{102}$, $-S(O)_2R^{102}$, $-SR^{101}$ and $-S(O)_2NR^{101}R^{102}$, optionally substituted with one or more independent R^{103} substituents; or R_3 and R_4, together with the atoms connecting R_3 and R_4, form a fused or non-fused mono, bicyclic or tricyclic heterocyclic or carbocyclic ring which is optionally independently substituted with one or more R^{103} substituents;

R_5 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, oxide (=O), $-C(O)R^{101}$, $-C(O)OR^{101}$, $-C(O)NR^{101}R^{102}$, $-S(O)_2R^{102}$, $-SR^{101}$ and $-S(O)_2NR^{101}R^{102}$;

R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{13} and R_{14} are each independently selected from the group consisting of hydrogen, cyano, $-NO_2$, $-OR^{101}$, hydroxy, amino, alkyl, alkenyl, cycloalkyl, halogen, alkoxy, alkoxyalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, $-C(O)R^{101}$, $-C(O)OR^{101}$, $-C(O)NR^{101}R^{102}$, $-NR^{101}R^{102}$, $-NR^{101}S(O)_2R^{102}$, $-NR^{101}C(O)R^{102}$, $-S(O)_2R^{102}$, $-SR^{101}$ and $-S(O)_2NR^{101}R^{102}$, each optionally independently substituted with one or more independent R^{103} substituents; or any two or more substituents selected from the group consisting of R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{13} and R_{14} together with the atoms connecting the same, form a fused or non-fused mono, bicyclic or tricyclic heterocyclic or carbocyclic ring which is optionally independently substituted with one or more R^{103} substituents; and

R^{101}, R^{102} and R^{103} are each independently selected from the group consisting of hydrogen, cyano, $-NO_2$, $-OR^{104}$, hydroxy, amino, alkyl, alkenyl, cycloalkyl, halogen, alkoxy, alkoxyalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, $-C(O)R^{104}$, $-C(O)OR^{104}$, $-C(O)NR^{104}R^{105}$, $-NR^{104}R^{105}$, $-NR^{104}S(O)_2R^{105}$, $-NR^{104}C(O)R^{105}$, $-S(O)_2R^{104}$, $-SR^{104}$ and $-S(O)_2NR^{104}R^{105}$, each optionally independently substituted with one or more independent R^{103} substituents; or R^{101}, R^{102}, together with the atoms connecting the same, form a fused or non-fused mono, bicyclic or tricyclic heterocyclic or carbocyclic ring which is optionally independently substituted with one or more R^{103} substituents; and

R^{104} and R^{105} are each independently selected from the group consisting of hydrogen, cyano, $-NO_2$, hydroxy, hydroxyalkyl, amino, alkyl, alkenyl, cycloalkyl, halogen, alkoxy, alkoxyalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt or adduct thereof, wherein R is aryl or heteroaryl.

3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt or adduct thereof, wherein R is selected from the group consisting of phenyl, naphthalene, tetrahydronaphthalenyl, indenyl, isoindenyl, indanyl, anthracenyl, phenanthrenyl, benzonaphthenyl, fluorenyl, indolizinyl, pyrindinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, naphthyridinyl, pyridopyridinyl, pteridinyl, indolyl, isoindolyl, indoleninyl, isoindazolyl,

benzazinyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl, benzopyranyl, benzothiopyranyl, benzoxazolyl, indoxazinyl, anthranilyl, benzodioxolyl, benzodioxanyl, benzoxadiazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, isobenzothienyl, benzothiazolyl, benzothiadiazolyl, benzimidazolyl, benzotriazolyl, benzoxazinyl, benzisoxazinyl, and tetrahydroisoquinolinyl, which is optionally independently substituted with from one to six substituents independently selected from the group consisting of hydrogen, halogen, alkoxy, haloalkyl, cyano, $-NO_2$, $-OR^{101}$, hydroxy, amino, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, $-C(O)R^{101}$, $-C(O)OR^{101}$, $-C(O)NR^{101}R^{102}$, $-NR^{101}R^{102}$, $-NR^{101}S(O)_2R^{102}$, $-NR^{101}C(O)R^{102}$, $-S(O)_2R^{102}$, $-SR^{101}$ and $-S(O)_2NR^{101}R^{102}$.

4. The compound of any of one of claims 1 to 3, or a pharmaceutically acceptable salt or adduct thereof, wherein R is phenyl or naphthalene which is optionally independently substituted with from one to six substituents independently selected from the group consisting of hydrogen, chloro, fluoro, bromo, trifluoromethyl, cyano, methoxy, ethoxy, methyl and ethyl.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt or adduct thereof, wherein R_1 is selected from the group consisting of hydrogen, alkoxy, alkoxyalkyl, $-OR^{101}$, hydroxy, hydroxyalkyl, amino, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt or adduct thereof, wherein R_1 is selected from the group consisting of alkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl and heteroarylalkyl.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt or adduct thereof, wherein R_1 is selected from the group consisting of methyl, $-CH_2OH$, and $-CH_2-O-CH_2$-phenyl.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt or adduct thereof, wherein R_3 is hydrogen, alkyl or cycloalkyl.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt or adduct thereof, wherein R_4 is selected from the group consisting of alkyl, cycloalkyl, hydroxy, amino, alkoxy, alkylamino, aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl and aminoalkyl.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt or adduct thereof, wherein R_4 is methyl, ethyl, benzyl, or benzyl substituted with from one to five

substituents independently selected from the group consisting of methyl, fluoro, chloro, trifluoromethyl, methoxy, cyano and hydroxy.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt or adduct thereof, wherein R_5 is selected from the group consisting of alkyl, cycloalkyl, oxide (=O), aryl, arylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, -$C(O)R^{101}$, -$C(O)OR^{101}$ and -$C(O)NR^{101}R^{102}$.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt or adduct thereof, wherein R_5 is methyl.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt or adduct thereof, wherein R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{13} and R_{14} are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, -$C(O)OR^{101}$, and -alkylOR^{103}.

14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt or adduct thereof, wherein R_8 and R_9 are each independently hydrogen, alkyl, cycloalkyl, -$C(O)OR^{101}$, or -alkylOR^{103}.

15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt or adduct thereof, wherein R_8 and R_9 are each independently hydrogen, methyl, ethyl, -C(=O)OEt, or $-CH_2OH$.

16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt or adduct thereof, wherein R_8 and R_9, together with the atom connecting them, form a cycloalkyl ring.

17. The compound of claim 16, or a pharmaceutically acceptable salt or adduct thereof, wherein said cycloalkyl ring is cyclopropane.

18. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt or adduct thereof, selected from the group consisting of:

GA1		1-methyl-3-((R)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA2		1-methyl-3-((S)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,

GA3		1-methyl-3-(1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA4		3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA5		1-benzyl-3-((R)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA6		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA7		3-(1-(2,3-dichlorophenyl)ethyl)-1-(2-fluorobenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA8		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA9		3-(1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA10		3-((R)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,

GA11		1-benzyl-3-(1-(2,3-dichlorophenyl)propyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA12		3-((S)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA13		3-((R)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA14		3-(1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA15		1-benzyl-3-((S)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA16		1-benzyl-3-((R)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA17		1-benzyl-3-(1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA18		3-(1-(2,3-dichlorophenyl)propyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,

GA19		3-(1-(2,3-difluorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA20		1-benzyl-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA21		1-benzyl-3-(1-(2,3-difluorophenyl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA22		1-benzyl-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA23		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA24		3-(1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,2,2,5,5-pentamethylpiperidin-4-yl)urea,
GA25		methyl 2-(3-methyl-3-(1,3,3-trimethylpiperidin-4-yl)ureido)-2-(naphthalen-1-yl)acetate,
GA26		3-(2-hydroxy-1-(naphthalen-1-yl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,

GA27		1-(4-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA28		1-benzyl-1-(3,3-diethyl-1-methylpiperidin-4-yl)-3-((S)-1-(naphthalen-1-yl)ethyl)urea,
GA29		1-benzyl-1-(3,3-diethyl-1-methylpiperidin-4-yl)-3-((R)-1-(naphthalen-1-yl)ethyl)urea,
GA30		1-benzyl-1-(3,3-diethyl-1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA31		3-(2-(benzyloxy)-1-(naphthalen-1-yl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA32		ethyl 4-(1-benzyl-3-(1-(2,3-dichlorophenyl)ethyl)ureido)-1,3-dimethylpiperidine-3-carboxylate,
GA33		3-((R)-1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,

GA34		3-(2-cyclopropyl-1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA35		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-hydroxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA36		1-benzyl-3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-(hydroxymethyl)-1,3-dimethylpiperidin-4-yl)urea,
GA37		1-benzyl-3-(1-(2,3-dihydroxyphenyl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA38		3-((R)-1-(2,3-dichlorophenyl)ethyl)-1-(3-(2-hydroxyethoxy)benzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA39		3-(1-(2,3-difluoro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA40		3-(1-(2,3-difluoro-4-hydroxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,

GA41		4-(1-benzyl-3-(1-(2,3-dichlorophenyl)ethyl)ureido)-1,3-dimethylpiperidine-3-carboxylic acid,
GA42		ethyl 4-(3-(1-(2,3-dichlorophenyl)ethyl)-1-methylureido)-1,3-dimethylpiperidine-3-carboxylate,
GA43		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-(hydroxymethyl)-1,3-dimethylpiperidin-4-yl)-1-methylurea,
GA44		4-(3-(1-(2,3-dichlorophenyl)ethyl)-1-methylureido)-1,3,3-trimethylpiperidine 1-oxide,
GA45		3-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)-1-benzyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA46		1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA47		3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA48		3-(2-hydroxy-1-(naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA49		3-(2-hydroxy-1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA50		1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)-1-(pyridin-3-ylmethyl)urea,
GA51		1-cyclopentyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA52		1-methyl-3-(1-(naphthalen-1-yl)ethyl)-1-(piperidin-4-yl)urea,
GA53		1-(1-acetylpiperidin-4-yl)-1-methyl-3-(1-(naphthalen-1-yl)ethyl)urea,
GA54		1-methyl-1-(1-(methylsulfonyl)piperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA55		1-methyl-3-(1-(naphthalen-1-yl)ethyl)-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)urea,
GA56		1-cyclohexyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,

GA57		1-(cyclohexylmethyl)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA58		1-isopropyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA59		1-(2-methoxyethyl)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA60		1-(1-ethylpiperidin-4-yl)-1-methyl-3-(1-(naphthalen-1-yl)ethyl)urea,
GA61		1-ethyl-4-(1-methyl-3-(1-(naphthalen-1-yl)ethyl)ureido)piperidine 1-oxide,
GA62		1-(cyclopropylmethyl)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA63		3-(1-(2-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA64		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(quinolin-4-yl)ethyl)urea,
GA65		tert-butyl 4-(1-methyl-3-(1-(naphthalen-1-yl)ethyl)ureido)piperidine-1-carboxylate,

GA66		1-(1-formylpiperidin-4-yl)-1-methyl-3-(1-(naphthalen-1-yl)ethyl)urea,
GA67		3-(2-methoxy-1-(naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA68		3-(3-methoxy-1-(naphthalen-1-yl)propyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA69		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)propyl)urea,
GA70		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(quinolin-5-yl)ethyl)urea,
GA71		1-methyl-1-(1-methylpiperidin-4-yl)-3-(2-(naphthalen-1-yl)propan-2-yl)urea,
GA72		3-(1-(2-chloroquinolin-4-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA73		(S)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)-1-(pyridin-3-ylmethyl)urea,

GA74		(R)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)-1-(pyridin-3-ylmethyl)urea,
GA75		1-isobutyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA76		1-(cyclobutylmethyl)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA77		1-butyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA78		3-(1-(2-methoxyquinolin-4-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA79		1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)-1-(pyridin-2-ylmethyl)urea,
GA80		1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)-1-(pyridin-4-ylmethyl)urea,
GA81		(S)-1-ethyl-3-(1-(2-methoxyquinolin-4-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,

GA82		(R)-1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA83		3-(2-hydroxy-1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA84		3-(2-hydroxy-1-(naphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)-1-(pyridin-3-ylmethyl)urea,
GA85		3-(2-methoxy-1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA86		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-hydroxybenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA87		1-benzyl-1-(1,3-dimethylpiperidin-4-yl)-3-((R)-1-(naphthalen-1-yl)ethyl)urea,
GA88		1-(1,3-dimethylpiperidin-4-yl)-1-methyl-3-((R)-1-(naphthalen-1-yl)ethyl)urea,
GA89		3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA90		(R)-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA91		(S)-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA92		3-(1-(4,8-dimethoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA93		3-(1-(4-(methoxymethoxy)naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA94		3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA95		(R)-3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA96		(S)-3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA97		3-(1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA98		1-benzyl-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,

GA99		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-fluorobenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA100		1-(2-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA101		3-(1-(3,5-difluorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA102		3-(1-(2-chlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA103		3-(1-(3-fluorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA104		3-(1-(4-chlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA105		3-(1-(2,4-difluorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA106		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(o-tolyl)ethyl)urea,
GA107		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(4-(methylsulfonyl)phenyl)ethyl)urea,

GA108		1-(cyclohexylmethyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA109		1-(cyclopropylmethyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA110		3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA111		3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)-1-(pyridin-3-ylmethyl)urea,
GA112		3-(1-(3-chlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA113		1-benzyl-3-(1-(3-chlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA114		1-(3-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA115		3-(1-(2,3-dichlorophenyl)ethyl)-1-(2-methoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,

GA116		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA117		3-(1-(2,3-dichlorophenyl)ethyl)-1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA118		3-(1-(2,3-dichlorophenyl)ethyl)-1-(2-fluorobenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA119		1-(4-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA120		3-(1-(3,4-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA121		3-(1-(2,3-dichlorophenyl)ethyl)-1-(4-methoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA122		3-(1-(2,3-dichlorophenyl)propyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA123		1-(cyclohexylmethyl)-3-(1-(2,3-dichlorophenyl)propyl)-1-(1-methylpiperidin-4-yl)urea,

GA124		3-(1-(2,3-difluorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA125		1-benzyl-3-(1-(2,3-difluorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA126		1-(cyclohexylmethyl)-3-(1-(2,3-difluorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA127		(R)-3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA128		1-benzyl-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)urea,
GA129		3-(1-(2,3-dichlorophenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-methylurea,
GA130		(S)-3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA131		(R)-3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,

GA132		3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA133		3-((R)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,
GA134		3-((S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,
GA135		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,
GA136		3-(1-(2,3-difluorophenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,
GA137		3-(1-(2,3-dichlorophenyl)ethyl)-1-(4-(hydroxymethyl)benzyl)-1-(1-methylpiperidin-4-yl)urea,
GA138		methyl 4-((3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)ureido)methyl)benzoate,
GA139		3-(2-cyclopropyl-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA140		3-(1-(2,3-dichlorophenyl)-2-hydroxyethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA141		(R)-1-(2-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA142		(S)-1-(2-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA143		1-(2-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA144		3-(1-(2,3-dimethoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA145		3-(1-(2,3-difluoro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA146		3-(1-(2,3-dichlorophenyl)-2-methoxyethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA147		N-(2,3-dichloro-4-(1-(3-methyl-3-(1-methylpiperidin-4-yl)ureido)ethyl)phenyl)acetamide,

GA148		3-(1-(4-amino-2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA149		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA150		1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)-3-(3-(pyridin-3-yloxy)phenyl)propyl)urea,
GA151		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)-3-(pyridin-3-yl)propyl)urea,
GA152		1-methyl-1-(1-methylpiperidin-4-yl)-3-(3-morpholino-1-(naphthalen-1-yl)propyl)urea,
GA153		1-ethyl-3-(3-(3-methoxyphenyl)-1-(naphthalen-1-yl)propyl)-1-(1-methylpiperidin-4-yl)urea,

GA154		3-(3-(3-(benzyloxy)phenyl)-1-(naphthalen-1-yl)propyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA155		1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)-3-(pyridin-3-yl)propyl)urea,
GA156		3-(3-(3-(benzyloxy)phenyl)-1-(naphthalen-1-yl)propyl)-1-(1-methylpiperidin-4-yl)-1-(pyridin-3-ylmethyl)urea,
GA157		3-(3-(3-(benzyloxy)phenyl)-1-(2,3-dichlorophenyl)propyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA158		3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA159		3-(2-(benzylamino)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA160		3-(1-(2,3-dichlorophenyl)-2-((3-(hydroxymethyl)benzyl)oxy)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA161		3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-(2-chlorobenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA162		3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-(4-(hydroxymethyl)benzyl)-1-(1-methylpiperidin-4-yl)urea,
GA163		3-(1-(2,3-dichlorophenyl)-2-((4-methoxybenzyl)oxy)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA164		3-(1-(2,3-dichlorophenyl)-2-(pyridin-4-ylmethoxy)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA165		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,
GA166		(S)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,

GA167		(R)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,
GA168		1-hydroxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA169		(R)-1-hydroxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA170		(S)-1-hydroxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA171		3-(1-(2,3-dichlorophenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,
GA172		(R)-3-(1-(2,3-dichlorophenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,
GA173		(S)-3-(1-(2,3-dichlorophenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,
GA174		1-methoxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA175		(R)-1-methoxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,

GA176		(S)-1-methoxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA177		3-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA178		(R)-3-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA179		(S)-3-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA180		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA181		(R)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA182		(S)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA183		3-(1-(2,3-dichloro-4-(dimethylamino)phenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA184		3-(1-(4-((4-methoxybenzyl)oxy)naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA185		3-(1-(4-hydroxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA186		3-(1-(4,5-dimethoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA187		3-(1-(2,3-dichlorophenyl)-2-(pyridin-3-ylmethoxy)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA188		3-(1-(4-chlorobenzo[d][1,3]dioxol-5-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA189		3-(1-(2-chloro-3,4-dimethoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA190		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(2,3,4-trichlorophenyl)ethyl)urea,
GA191		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(4-(pyridin-4-ylmethoxy)naphthalen-1-yl)ethyl)urea,
GA192		3-(1-(6-chloro-[1,1'-biphenyl]-2-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA193		3-(1-(3-chloro-2-(pyridin-4-yl)phenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA194		3-(1-(2,3-dichloro-4-methylphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA195		3-(1-(3-chloro-2-methylphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA196		3-(1-(2,3-dichlorophenyl)-2-((4-(hydroxymethyl)benzyl)oxy)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA197		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA198		(R)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA199		(S)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA200		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,

GA201		3-((R)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA202		3-((S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea, and
GA203		3-(1-(4-(2-(benzyloxy)ethoxy)naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea.

19. Use of a compound of formula (I) according to any one of claims 1-18, or a pharmaceutically acceptable salt or adduct thereof, in the preparation of a medicament for treating a subjecthaving a disease which is pathophysiologically mediated by the ghrelin receptor.

20. The use of claim 19, wherein said disease is obesity, overweight, eating disorder, diabete, metabolic syndrome, cachexia resulting from cancer, congestive heart failure, wasting due to ageing or AIDS, chronic liver failure, chronic obstructive pulmonary disease, gastrointestinal disease, gastric disorder or substance abuse.

21. The use of claim 20, wherein said metabolic disorder is selected from the group consisting of diabetes, Type I diabetes, Type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, obesity, aging, Syndrome X, atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease.

22. The use of claim 20, wherein said gastric disorder is selected from the group consisting of Post-operative ileus (POI), diabetic gastroparesis, and opioid induced bowel dysfunction.

23. The use of claim 20, wherein said gastrointestinal disease is selected from the group consisting of irritable bowel syndrome, gastritis, acid reflux disease, gastroparesis, and functional dyspepsia.

24. The use of claim 20, wherein said substance abuse is alcohol or drug abuse.

25. The use of claim 24, wherein said drug is selected from the group consisting of amphetamines, barbiturates, benzodiazepines, cocaine, methaqualone, and opioids.

26. The use of any one of claims 19 to 25, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is a ghrelin receptor modulator.

27. The use of any one of claims 19 to 26, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is a ghrelin receptor agonist.

28. The use of any one of claims 19 to 27, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is a ghrelin receptor antagonist.

29. The use of any one of claims 19 to 28, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is administered by one or more routes selected from the group consisting of rectal, buccal, sublingual, intravenous, subcutaneous, intradermal, transdermal, intraperitoneal, oral, eye drops, parenteral and topical administration.

30. The use of any one of claims 19 to 29, wherein said administration is accomplished by administering an oral form of said compound or a pharmaceutically acceptable salt or adduct thereof.

31. The use of any one of claims 19 to 30, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is administered in an amount of from about 0.01 microgram per Kg (μg/Kg) body weight per day to about 100 mg/Kg body weight per day, from about 0.1 μg /Kg/day to about 10 mg/Kg/day, from about 1 μg /Kg /day to about 5 mg/ Kg /day, from about 10 μg /Kg/day to about 5 mg/Kg/day, from about 100 μg /Kg/day to about 5 mg/Kg/day, or from about 500 μg /Kg/day to about 5 mg/Kg/day.

32. The use of any one of claims 19 to 31, further comprising administering one or more therapeutic agents.

33. The use of any one of claims 19 to 32, wherein the subject is a human.

34. The use of any one of claims 19 to 33, wherein the subject has been identified as needing treatment for the disease or the administration.

35. A pharmaceutical composition for preventing and/or treating a subject comprising a therapeutically effective amount of a compound according to any one of claims 1-18, and one or more pharmaceutically acceptable excipients.

CLAIMS

1. A compound of formula



or a pharmaceutically acceptable salt thereof,

wherein:

R is aryl optionally substituted with one or more independent R^{103} substituents;

$\mathbf{R_1}$ is selected from the group consisting of hydroxyalkyl, alkyl, optionally substituted with one or more independent R^{103} substituents;

$\mathbf{R_4}$ is selected from the group consisting of alkyl, aryl, arylalkyl, optionally substituted with one or more independent R^{103} substituents; or R_4 is OR^{103} ;

$\mathbf{R_6, R_7, R_8, R_9}$ are selected from the group consisting of hydrogen and alkyl;

$\mathbf{R^{103}}$ is selected from the group consisting of hydrogen, cyano, $-NO_2$, $-OR^{104}$, hydroxy, amino, alkyl, alkenyl, cycloalkyl, halogen, alkoxy, alkoxyalkyl, aryl, arylalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, $-C(O)R^{104}$, $-C(O)OR^{104}$, $-C(O)NR^{104}R^{105}$, $-NR^{104}R^{105}$, $-NR^{104}S(O)_2R^{105}$, $-NR^{104}C(O)R^{105}$, $-S(O)_2R^{104}$, $-SR^{104}$ and $-S(O)_2NR^{104}R^{105}$, each optionally independently substituted with one or more independent R^{103} substituents; and

R^{104} and R^{105} are each independently selected from the group consisting of hydrogen, cyano, NO_2, hydroxy, hydroxyalkyl, amino, alkyl, alkenyl, cycloalkyl, halogen, alkoxy, alkoxyalkyl, aryl, arylalkyl, heterocycloalkyl, heteroaryl and heteroarylalkyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:

when R is aryl optionally substituted with R^{103}, then R^{103} is halogen or alkoxy;
when R_4 is alkyl, aryl, arylalkyl optionally substituted with R^{103}, then R^{103} is halogen or alkoxy;
or when R_4 is OR^{103}, then R^{103} is hydrogen or alkyl.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of phenyl, naphthalene, tetrahydronaphthalenyl, indenyl, isoindenyl, indanyl, anthracenyl, phenanthrenyl, benzonaphthenyl, fluorenyl.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is phenyl or naphthalene which is optionally independently substituted with from one to six substituents independently selected from the group consisting of chloro, fluoro, bromo, methoxy and ethoxy.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R_1 is selected from the group consisting of methyl, $-CH_2OH$, and $-CH_2-O-CH_2$-phenyl.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R_4 is methyl, ethyl, benzyl, or benzyl substituted with from one to five

substituents independently selected from the group consisting of methyl, fluoro, chloro, trifluoromethyl, methoxy, cyano and hydroxy.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R_8 and R_9 are each independently hydrogen, methyl, or ethyl.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

GA1		1-methyl-3-((R)-1-(naphthalen-1-yl) ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA2		1-methyl-3-((S)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA3		1-methyl-3-(1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl) urea,
GA4		3-(1-(4-methoxynaphthalen-1-yl)eth yl)-1-methyl-1-(1,3,3-trimethylpiperi din-4-yl)urea,
GA5		1-benzyl-3-((R)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA6		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpi peridin-4-yl)urea,

GA7		3-(1-(2,3-dichlorophenyl)ethyl)-1-(2-fluorobenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA8		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA9		3-(1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA10		3-((R)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,
GA11		1-benzyl-3-(1-(2,3-dichlorophenyl)propyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA12		3-((S)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA13		3-((R)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA14		3-(1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,

GA15		1-benzyl-3-((S)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA16		1-benzyl-3-((R)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA17		1-benzyl-3-(1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl) urea,
GA18		3-(1-(2,3-dichlorophenyl)propyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA19		3-(1-(2,3-difluorophenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl) urea,
GA20		1-benzyl-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl) urea,
GA21		1-benzyl-3-(1-(2,3-difluorophenyl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl) urea,

GA22		1-benzyl-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA23		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA24		3-(1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1,2,2,5,5-pentamethylpiperidin-4-yl)urea,
GA26		3-(2-hydroxy-1-(naphthalen-1-yl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA27		1-(4-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA28		1-benzyl-1-(3,3-diethyl-1-methylpiperidin-4-yl)-3-((S)-1-(naphthalen-1-yl)ethyl)urea,
GA29		1-benzyl-1-(3,3-diethyl-1-methylpiperidin-4-yl)-3-((R)-1-(naphthalen-1-yl)ethyl)urea,

GA30		1-benzyl-1-(3,3-diethyl-1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA31		3-(2-(benzyloxy)-1-(naphthalen-1-yl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA33		3-((R)-1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA34		3-(2-cyclopropyl-1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA35		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-hydroxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA37		1-benzyl-3-(1-(2,3-dihydroxyphenyl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA38		3-((R)-1-(2,3-dichlorophenyl)ethyl)-1-(3-(2-hydroxyethoxy)benzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea,

GA39		3-(1-(2,3-difluoro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3,3-trimethylpi peridin-4-yl)urea,
GA40		3-(1-(2,3-difluoro-4-hydroxyphenyl) ethyl)-1-methyl-1-(1,3,3-trimethylpi peridin-4-yl)urea,
GA44		4-(3-(1-(2,3-dichlorophenyl)ethyl)-1-methylureido)-1,3,3-trimethylpiperid ine 1-oxide,
GA46		1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA47		3-(1-(4-methoxynaphthalen-1-yl)eth yl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA48		3-(2-hydroxy-1-(naphthalen-1-yl)eth yl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA49		3-(2-hydroxy-1-(4-methoxynaphthal en-1-yl)ethyl)-1-methyl-1-(1-methyl piperidin-4-yl)urea,
GA50		1-(1-methylpiperidin-4-yl)-3-(1-(nap hthalen-1-yl)ethyl)-1-(pyridin-3-ylm ethyl)urea,
GA57		1-(cyclohexylmethyl)-1-(1-methylpi peridin-4-yl)-3-(1-(naphthalen-1-yl)e thyl)urea,

GA58		1-isopropyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA59		1-(2-methoxyethyl)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA62		1-(cyclopropylmethyl)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA63		3-(1-(2-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA67		3-(2-methoxy-1-(naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA68		3-(3-methoxy-1-(naphthalen-1-yl)propyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA69		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)propyl)urea,
GA73		(S)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)-1-(pyridin-3-ylmethyl)urea,
GA74		(R)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)-1-(pyridin-3-ylmethyl)urea,

GA75		1-isobutyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA76		1-(cyclobutylmethyl)-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA77		1-butyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA79		1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)-1-(pyridin-2-ylmethyl)urea,
GA80		1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)-1-(pyridin-4-ylmethyl)urea,
GA82		(R)-1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)ethyl)urea,
GA83		3-(2-hydroxy-1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA84		3-(2-hydroxy-1-(naphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)-1-(pyridin-3-ylmethyl)urea,

GA85		3-(2-methoxy-1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA86		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-hydroxybenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA87		1-benzyl-1-(1,3-dimethylpiperidin-4-yl)-3-((R)-1-(naphthalen-1-yl)ethyl)urea,
GA88		1-(1,3-dimethylpiperidin-4-yl)-1-methyl-3-((R)-1-(naphthalen-1-yl)ethyl)urea,
GA89		3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA90		(R)-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA91		(S)-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA92		3-(1-(4,8-dimethoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA93		3-(1-(4-(methoxymethoxy)naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA94		3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA95		(R)-3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA96		(S)-3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA97		3-(1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA98		1-benzyl-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA99		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-fluorobenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA100		1-(2-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA101		3-(1-(3,5-difluorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA102		3-(1-(2-chlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA103		3-(1-(3-fluorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA104		3-(1-(4-chlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA105		3-(1-(2,4-difluorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA106		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(o-tolyl)ethyl)urea,
GA107		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(4-(methylsulfonyl)phenyl)ethyl)urea,
GA108		1-(cyclohexylmethyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA109		1-(cyclopropylmethyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA110		3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA111		3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)-1-(pyridin-3-ylmethyl)urea,

GA112		3-(1-(3-chlorophenyl)ethyl)-1-methy l-1-(1-methylpiperidin-4-yl)urea,
GA113		1-benzyl-3-(1-(3-chlorophenyl)ethyl) -1-(1-methylpiperidin-4-yl)urea,
GA114		1-(3-chlorobenzyl)-3-(1-(2,3-dichlor ophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA115		3-(1-(2,3-dichlorophenyl)ethyl)-1-(2-methoxybenzyl)-1-(1-methylpiperidi n-4-yl)urea,
GA116		3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1-methylpiperidi n-4-yl)urea,
GA117		3-(1-(2,3-dichlorophenyl)ethyl)-1-(4-fluorobenzyl)-1-(1-methylpiperidin-4 -yl)urea,
GA118		3-(1-(2,3-dichlorophenyl)ethyl)-1-(2-fluorobenzyl)-1-(1-methylpiperidin-4 -yl)urea,
GA119		1-(4-chlorobenzyl)-3-(1-(2,3-dichlor ophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,

GA120		3-(1-(3,4-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA121		3-(1-(2,3-dichlorophenyl)ethyl)-1-(4-methoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA122		3-(1-(2,3-dichlorophenyl)propyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA123		1-(cyclohexylmethyl)-3-(1-(2,3-dichlorophenyl)propyl)-1-(1-methylpiperidin-4-yl)urea,
GA124		3-(1-(2,3-difluorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA125		1-benzyl-3-(1-(2,3-difluorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA126		1-(cyclohexylmethyl)-3-(1-(2,3-difluorophenyl)ethyl)-1-(1-methylpiperidin-4-yl) urea,
GA127		(R)-3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl) urea,

GA128		1-benzyl-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)urea,
GA129		3-(1-(2,3-dichlorophenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-methyl urea,
GA130		(S)-3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA131		(R)-3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA132		3-(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA133		3-((R)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,
GA134		3-((S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,
GA135		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,

GA136		3-(1-(2,3-difluorophenyl)ethyl)-1-(1,3-dimethylpiperidin-4-yl)-1-(3-methoxybenzyl)urea,
GA137		3-(1-(2,3-dichlorophenyl)ethyl)-1-(4-(hydroxymethyl)benzyl)-1-(1-methylpiperidin-4-yl)urea,
GA138		methyl 4-((3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)ureido)methyl)benzoate,
GA139		3-(2-cyclopropyl-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA140		3-(1-(2,3-dichlorophenyl)-2-hydroxyethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA141		(R)-1-(2-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA142		(S)-1-(2-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA143		1-(2-chlorobenzyl)-3-(1-(2,3-dichlorophenyl)ethyl)-1-(1-methylpiperidin-4-yl)urea,

GA144		3-(1-(2,3-dimethoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA145		3-(1-(2,3-difluoro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA146		3-(1-(2,3-dichlorophenyl)-2-methoxyethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA147		N-(2,3-dichloro-4-(1-(3-methyl-3-(1-methylpiperidin-4-yl)ureido)ethyl)phenyl)acetamide,
GA148		3-(1-(4-amino-2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA149		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA150		1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)-3-(3-(pyridin-3-yloxy)phenyl)propyl)urea,
GA151		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)-3-(pyridin-3-yl)propyl)urea,

GA152		1-methyl-1-(1-methylpiperidin-4-yl)-3-(3-morpholino-1-(naphthalen-1-yl)propyl)urea,
GA153		1-ethyl-3-(3-(3-methoxyphenyl)-1-(naphthalen-1-yl)propyl)-1-(1-methylpiperidin-4-yl)urea,
GA154		3-(3-(3-(benzyloxy)phenyl)-1-(naphthalen-1-yl)propyl)-1-ethyl-1-(1-methylpiperidin-4-yl)urea,
GA155		1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)-3-(pyridin-3-yl)propyl)urea,
GA156		3-(3-(3-(benzyloxy)phenyl)-1-(naphthalen-1-yl)propyl)-1-(1-methylpiperidin-4-yl)-1-(pyridin-3-ylmethyl)urea,
GA157		3-(3-(3-(benzyloxy)phenyl)-1-(2,3-dichlorophenyl)propyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA158		3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA159		3-(2-(benzylamino)-1-(2,3-dichlorophenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA161		3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-(2-chlorobenzyl)-1-(1-methylpiperidin-4-yl)urea,
GA162		3-(2-(benzyloxy)-1-(2,3-dichlorophenyl)ethyl)-1-(4-(hydroxymethyl)benzyl)-1-(1-methylpiperidin-4-yl)urea,
GA163		3-(1-(2,3-dichlorophenyl)-2-((4-methoxybenzyl)oxy)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA164		3-(1-(2,3-dichlorophenyl)-2-(pyridin-4-ylmethoxy)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA165		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,

GA166		(S)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,
GA167		(R)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,
GA168		1-hydroxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA169		(R)-1-hydroxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA170		(S)-1-hydroxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA171		3-(1-(2,3-dichlorophenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl) urea,
GA172		(R)-3-(1-(2,3-dichlorophenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl)urea,
GA173		(S)-3-(1-(2,3-dichlorophenyl)ethyl)-1-methoxy-1-(1-methylpiperidin-4-yl) urea,
GA174		1-methoxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA175		(R)-1-methoxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,

GA176		(S)-1-methoxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea,
GA177		3-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl) urea,
GA178		(R)-3-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA179		(S)-3-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl) urea,
GA180		3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA181		(R)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA182		(S)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea,
GA183		3-(1-(2,3-dichloro-4-(dimethylamino)phenyl)ethyl)-1-methyl-1-(1-methyl piperidin-4-yl)urea,
GA184		3-(1-(4-((4-methoxybenzyl)oxy)naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA185		3-(1-(4-hydroxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA186		3-(1-(4,5-dimethoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea,
GA187		3-(1-(2,3-dichlorophenyl)-2-(pyridin-3-ylmethoxy)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA189		3-(1-(2-chloro-3,4-dimethoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA190		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(2,3,4-trichlorophenyl)ethyl) urea,
GA191		1-methyl-1-(1-methylpiperidin-4-yl)-3-(1-(4-(pyridin-4-ylmethoxy)naphthalen-1-yl)ethyl)urea,
GA192		3-(1-(6-chloro-[1,1'-biphenyl]-2-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA193		3-(1-(3-chloro-2-(pyridin-4-yl)phenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,

GA194		3-(1-(2,3-dichloro-4-methylphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA195		3-(1-(3-chloro-2-methylphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA196		3-(1-(2,3-dichlorophenyl)-2-((4-(hydroxymethyl)benzyl)oxy)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA197		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA198		(R)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA199		(S)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea,
GA200		3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA201		3-((R)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA202		3-((S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea, and

GA203		3-(1-(4-(2-(benzyloxy)ethoxy)naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea.

9. The use of a compound oaccording to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for preventing and/or treating a disease which is pathophysiologically mediated by the ghrelin receptor in a subject, wherein said disease comprises obesity, overweight, eating disorder, diabete, metabolic syndrome, cachexia resulting from cancer, congestive heart failure, wasting due to ageing or AIDS, chronic liver failure, chronic obstructive pulmonary disease, gastrointestinal disease, gastric disorder or substance abuse.

10. The use of claim 9, wherein said metabolic disorder is selected from the group consisting of diabetes, Type I diabetes, Type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, obesity, aging, Syndrome X, atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease.

11. The use of claim 9, wherein said gastric disorder is selected from the group consisting of Post-operative ileus (POI), diabetic gastroparesis, and opioid induced bowel dysfunction.

12. The use of claim 9, wherein said gastrointestinal disease is selected from the group consisting of irritable bowel syndrome, gastritis, acid reflux disease, gastroparesis, and functional dyspepsia.

13. The use of claim 9, wherein said substance abuse is alcohol or drug abuse.

14. The use of claim 13, wherein said drug is selected from the group consisting of amphetamines, barbiturates, benzodiazepines, cocaine, methaqualone, and opioids.

15. The use of any one of claims 9 to 14, wherein said compound or a pharmaceutically acceptable salt thereof, is a ghrelin receptor modulator.

16. The use of any one of claims 9 to 15, wherein said compound or a pharmaceutically acceptable salt thereof, is a ghrelin receptor agonist.

17. The use of any one of claims 9 to 15, wherein said compound or a pharmaceutically acceptable salt thereof, is a ghrelin receptor antagonist.

18. The use of any one of claims 9 to 17, wherein said medicament is for administration by one or more routes selected from the group consisting of rectal, buccal, sublingual, intravenous, subcutaneous, intradermal, transdermal, intraperitoneal, oral, eye drops, parenteral and topical administration.

19. The use of any one of claims 9 to 18, wherein said medicament is an oral formulation.

20. The use of any one of claims 9 to 19, wherein said compound or a pharmaceutically acceptable salt thereof in the medicament is for administration in an amount of from 0.01 microgram per Kg (μg/Kg) body weight per day to 100 mg/Kg body weight per day, from 0.1 μg /Kg/day to 10 mg/Kg/day, from 1 μg /Kg /day to 5 mg/ Kg /day, from 10 μg /Kg/day to 5 mg/Kg/day, from 100 μg /Kg/day to 5 mg/Kg/day, or from 500 μg /Kg/day to 5 mg/Kg/day.

21. The use of any one of claims 9 to 20, wherein the medicament is for administration with one or more therapeutic agents.

22. The use of any one of claims 9 to 21, wherein the subject is a human.

23. The use of any one of claims 9 to 22, wherein the subject has been identified as needing treatment for the disease or the administration.

24. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1- 8, and one or more pharmaceutically acceptable excipients for use in preventing and/or treating a disease in a subject.